METHODS: Here we analyze long-term survival from patients, who underwent resection of histologically confirmed epithelial non-ductal non-neuroendocrine neoplasms of the pancreas. At our department between Jan 1st, 1999, and Dec 31st, 2019. The median follow-up was 61 (range 0-168) month. All statistical analyses were performed using SPSS 26.0 (IBM, Chicago, IL, USA) software.
RESULTS: 46 patients (48%) were followed up for more than 5 years, 18 patients (19%) for more than 10 years. The 5-year and 10-year survival rates for rare non-invasive pancreatic tumours were 72% and 55% respectively. The proportion of rare tumour entities (non-ductal and non-neuroendocrine) increased continuously and statistically significantly (p = 0.004) from 4.2 to 12.3% in our clinic between 1999 and 2019. If there is no invasive growth yet, there is a varying risk of malignant degeneration in the course of the disease. Therefore, the indication for pancreatic resection is still the subject of discussion.
CONCLUSIONS: The long-term prognosis of rare epithelial pancreatic tumours after R0 resection-even if they are already malignant-is much better than that of ductal pancreatic cancer.
方法:在这里,我们分析了患者的长期生存率,接受组织学证实的胰腺上皮非导管非神经内分泌肿瘤切除术的患者。1月1日之间在我们部门,1999年和12月31日,2019.中位随访时间为61(范围0-168)个月。所有统计分析均使用SPSS26.0(IBM,芝加哥,IL,美国)软件。
结果:46例(48%)随访5年以上,18例(19%)患者10年以上。罕见的非侵袭性胰腺肿瘤的5年和10年生存率分别为72%和55%。在1999年至2019年期间,我们的诊所中罕见肿瘤实体(非导管和非神经内分泌)的比例从4.2%连续增加到12.3%(p=0.004)。如果还没有侵入性生长,在疾病的过程中,恶性变性的风险各不相同。因此,胰腺切除的适应症仍是讨论的主题.
结论:R0切除后的罕见上皮性胰腺肿瘤的长期预后-即使它们已经是恶性的-比导管胰腺癌的预后要好得多。